Abstract 200P
Background
We hypothesized that COVID-19 infection and vaccination status impact survival and pneumonitis risk in patients undergoing definitive chemoradiation and consolidative immunotherapy for locally advanced non-small cell lung cancer.
Methods
Following Institutional Review Board approval, patients with locally advanced non-small cell lung cancer (NSCLC) treated between June 8, 2017, and August 19, 2022 were screened using a prospectively maintained registry. Patients receiving concurrent chemoradiation and at least one cycle of consolidative durvalumab were included.
Results
Two hundred thirty-six patients met inclusion criteria. Of these patients, 121 (51.3%) were men and 115 (48.7%) were female. Twentythree patients (9.7%) were never smokers, 111 (47%) were former smokers, and 102 (43.2%) were current smokers. Median physical radiation dose was 60 Gy (range 54–72). In terms of COVID-19 vaccination status, 175 (74%) patients were vaccinated with at least one dose prior to starting chemoradiation. At a median follow-up of 2.7 years, 40 (17%) patients experienced at least one COVID-19 infection following initiation of chemoradiation. Sixty-one patients (26%) developed pneumonitis. The cumulative incidence of pneumonitis at 3 years was 25.8%. COVID-19 infection and vaccination status did not influence risk of pneumonitis. Patients with COVID-19 infection were at greater risk of death [hazard ratio: 2.08 (95% confidence interval: 1.08–3.98), p=.028].
Conclusions
In patients with NSCLC receiving the PACIFIC regimen, COVID-19 infection status did not impact the risk of pneumonitis. COVID-19 infection was associated with a two-fold increased risk of mortality following lung cancer therapy.
Legal entity responsible for the study
Mayo Clinic Comprehensive Cancer Center.
Funding
Has not received any funding.
Disclosure
D. Owen: Non-Financial Interests, Institutional, Research Grant: Varian, AstraZeneca. All other authors have declared no conflicts of interest.